Open AccessAssociation of long‐term tacrolimus ( FK 506) therapy with abnormal megakaryocytosis, bone marrow fibrosis, and dyserythropoiesis
Author(s) -
Yang Zhongbo,
Loew Thomas,
Hammer Richard D.
Publication year - 2015
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.303
Subject(s) - tacrolimus , medicine , bone marrow , fibrosis , haematopoiesis , pure red cell aplasia , bone marrow aplasia , bone marrow transplant , pathology , immunology , stem cell , bone marrow transplantation , transplantation , biology , genetics
Key Clinical Message Haematopoietic abnormalities associated with tacrolimus are relatively rare with reversible pure red cell aplasia being the most common. We report for the first time, to our best knowledge, tacrolimus therapy associated with bone marrow fibrosis, abnormal megakaryocytosis, and dyserythopoiesis in a 17‐year‐old male treated with tacrolimus for nephrotic syndrome.